Nasal Decongestants Monograph Amendment On Sinusitis Claims Planned
This article was originally published in The Tan Sheet
Executive Summary
FDA is targeting June for a proposed amendment to the cough/cold nasal decongestant monograph regarding sinusitis claims, according to the agency's recently published "unified agenda.
You may also be interested in...
FDA Proposes “Sinusitis” Exclusion From OTC Nasal Decongestant Monograph
FDA is seeking to amend the OTC nasal decongestant monograph by removing the indications that reference "sinusitis," the agency announced in a proposed rule slated for publication in the Aug. 2 Federal Register
HHS “Unified Agenda” Shows FDA Lagging On OTC Actions
FDA will publish a final rule on dietary supplement good manufacturing practices in November, according to HHS' semi-annual "unified agenda" published in the Federal Register June 28
FDA Analgesic Safety Campaign Launches; Label Warnings Still In Progress
FDA launched a public educational campaign Jan. 22 warning consumers about the link between acetaminophen and liver damage, and potential renal and gastrointestinal problems associated with nonsteroidal anti-inflammatory use